Ahead of upcoming investor conferences, pharmaceutical distributor Cencora (NYSE:COR) formerly known as AmerisourceBergen, slightly increased its earnings outlook for fiscal year 2024 on Thursday to a level consistent with Street forecasts

For fiscal 2024, the Pennsylvania-based company projects its adjusted earnings per share to reach $13.60-$13.70 in diluted terms, up from its previous outlook of $13.55-$1.65, and compared to $13.60 in the consensus.

However, Cencora (COR) set its projection for adjusted operating income and adjusted diluted EPS growth at the lower end of the company’s long-term growth targets of 5%-8% and 8%-12%, respectively.

The firm cited anticipated year-over-year headwinds from COVID products as the primary reason for the adjustment and, to a lesser degree, the loss of an oncology customer expected in June following its planned acquisition.

Cencora (COR) also announced it extended its pharmaceutical supply agreement with Evernorth Health Services, Cigna’s (CI) Pharmacy Benefits Manager, for three years through September 2019.